 |
| Toxic Brew |
Via: NewsDay
A new wave of experimental vaccines is the medical community's latest hope against a powerful staph infection that kills more people in the U.S. than skin cancer and costs as much as $8 billion a year to treat.
A new wave of experimental vaccines is the medical community's latest hope against a powerful staph infection that kills more people in the U.S. than skin cancer and costs as much as $8 billion a year to treat.
Pfizer Inc. and GlaxoSmithKline Plc, two of the world's biggest drugmakers, and NovaDigm Therapeutics Inc., a closely held biotechnology company, are each testing novel vaccines to halt methicillin-resistant Staphylococcus aureus, or MRSA, long a dangerous infection in hospitals and nursing homes and which is now increasingly finding its way into daycare centers, schools and prisons.
The vaccines are in early studies and years away from possible approval. Two other drug companies have already tried and failed to make an effective vaccine, most recently Merck & Co. in 2011. Still, as infections spread, doctors are eager for a vaccine that works.
No comments:
Post a Comment